Flagship Harbor Advisors’s Intellia Therapeutics NTLA Stock Holding History

Flagship Harbor Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-280	Closed	-$5K	–	1317
2020 Q3	$5K	Hold	280	–	–	﹤0.01%	1539
2020 Q2	$5K	Sell	280 -200	-42%	-$3.4K	﹤0.01%	1585
2020 Q1	$6K	Buy	480 +330	+220%	+$4.45K	﹤0.01%	1379
2019 Q4	$2K	Hold	150	–	–	﹤0.01%	1731
2019 Q3	$2K	Hold	150	–	–	﹤0.01%	1690
2019 Q2	$2K	Hold	150	–	–	﹤0.01%	1695
2019 Q1	$2K	Hold	150	–	–	﹤0.01%	1686
2018 Q4	$2K	Hold	150	–	–	﹤0.01%	1654
2018 Q3	$4K	Hold	150	–	–	﹤0.01%	1761
2018 Q2	$4K	Buy	+150	New	+$3.63K	﹤0.01%	1708

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

AVAX

Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM

Flagship Harbor Advisors's NTLA Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2020, closing a stake of 280 shares — an estimated $5K sold.

Flagship Harbor Advisors first reported a position in NTLA in Q2 2018 and held it in 10 quarters. The position peaked at $6K in Q1 2020. 240 funds tracked by Wall St. Rank hold NTLA as of Q4 2020.

Flagship Harbor Advisors reported no remaining Intellia Therapeutics position as of Q4 2020 after selling out during the quarter.
Flagship Harbor Advisors sold 280 Intellia Therapeutics shares in Q4 2020, an estimated $5K.
Flagship Harbor Advisors first reported a position in Intellia Therapeutics in Q2 2018 and held it in 10 quarters.
Flagship Harbor Advisors's Intellia Therapeutics position peaked at $6K in Q1 2020.
240 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.